# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) is collaborating with Spanios on a non-clinical study using New Alternate M...
Sonnet BioTherapeutics (NASDAQ:SONN) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate...